drugset / Trial / NCT05506488
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
Timeline
- Start
- 2023-07-05
- Primary completion
- 2026-02-26
- Completion
- 2026-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Quercetin | Small molecule | 1000 mg | Oral |
| Comparator | dasatinib anhydrous | Small molecule | 100 mg | Oral |